本帖最后由 beiwei5du 于 2018-5-24 23:25 编辑
最近的P/E ratio又涨了(都大于300了),那么药明生物真的是被过高估值了吗??四处建厂,大量曝光的主要目的之一也是在于支撑现在的市值??
Is WuXi Biologics (Cayman) Inc’s (HKG:2269) Stock Available For A Good Price After Accounting For Growth?
Is 2269’s share price justified by its earnings growth?WuXi Biologics (Cayman) is trading at price-to-earnings (PE) ratio of 250.14x, this also tells us the stock is overvalued based on current earnings compared to the life sciences industry average of 40.42x , and overvalued compared to the HK market average ratio of 13.19x .
SEHK:2269 PE PEG Gauge Mar 29th 18After looking at 2269’s value based on current earnings, we can see it seems overvalued relative to other companies in the industry. However, since WuXi Biologics (Cayman) is a high-growth stock, we must also account for its earnings growth by using calculation called the PEG ratio. A PE ratio of 250.14x and expected year-on-year earnings growth of 49.58% give WuXi Biologics (Cayman) a punchy PEG ratio of 5.05x. This tells us that when we include its growth in our analysis WuXi Biologics (Cayman)’s stock can be considered somewhat overvalued , based on the fundamentals.
|